neuroClues, a MedTech company developing quantitative tools for neurological assessment, announced the close of a €10 million Series A financing round.
The investment brings the company’s total funding raised to €25 million and was led by Teampact Ventures, White Fund SA, and the EIC Fund (European Investment Bank), with continued support from invest.bw, LeanSquare, and Wallonie Entreprendre.
Related: Lifebloom secures €8M for exoskeleton walking therapy
The financing follows a year of significant clinical and commercial progress:
- CE certification (Class IIa) obtained for its device
- Rapid deployment across 7 European countries, including university hospitals, research centers, and neurology practices
- Growing adoption by clinicians seeking objective, quantitative data for neurological exams
- Large-scale clinical data accumulation to support detection of conditions such as Parkinson’s disease
- Integration into several clinical cohorts at the Institut du Cerveau – Paris Brain Institute
neuroClues aims to make neurological assessment fast, objective, and accessible for every clinician. The company’s broader ambition is to shift neurology toward earlier diagnosis and prevention – at a stage when interventions can still make a meaningful difference for patients.
NeuroClues® is a CE-marked Class IIa medical device by P3Lab that acts as a “brain stethoscope” by using AI-driven eye-tracking to provide objective, non-invasive biomarkers for early diagnosis and tracking of neurodegenerative disorders like Parkinson’s and Alzheimer’s.
Alongside institutional investors, neuroClues opened part of its capital to individual citizens through Lita. The response exceeded expectations: 90% of the initial crowdfunding target was reached within just two weeks.
